Aurore Morello
About
Aurore Morello is from Nantes, Pays de la Loire, France. Aurore works in the following industries: "Research Services". Aurore is currently Researcher at OSE Immunotherapeutics, located in Nantes Area, France. In Aurore's previous role as a Postdoctoral Research Scholar at Memorial Sloan Kettering Cancer Center, Aurore worked in New York, New York until Dec 2016. Prior to joining Memorial Sloan Kettering Cancer Center, Aurore was a Postdoctoral Fellow and PhD student at CNRS UMR 5164 and held the position of Postdoctoral Fellow and PhD student at Bordeaux Area, France.
You can find Aurore Morello's email at finalscout.com. FinalScout is a professional database with business professional profiles and company profiles.
Aurore Morello's current jobs
Aurore Morello's past jobs
Supervisor: Dr Prasad S. Adusumilli Projects focusing on overcoming immunosupression to enhance CAR T cell therapy for the treatment of solid tumors. Publications: 1- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. Cherkassky L and Morello A (co-first authors), Villena Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. J Clin Invest. 2016 Aug 1;126(8):3130-44. doi: 10.1172/JCI83092. Epub 2016 Jul 25.PMID: 27454297 http://www.ncbi.nlm.nih.gov/pubmed/27454297 2- Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Morello A, Sadelain M, Adusumilli PS. Cancer Discov. 2016 Feb;6(2):133-46. doi: 10.1158/2159-8290.CD-15-0583. Epub 2015 Oct 26. Review.PMID: 26503962 http://www.ncbi.nlm.nih.gov/pubmed/26503962
Supervisor: Pr Jean Luc Taupin Project: Design and Improvement of FasL-derived molecules that target and induce apoptosis of carcinoma cells Publications: 1-Enhancing production and cytotoxic activity of polymeric soluble FasL-based chimeric proteins by concomitant expression of soluble FasL. Morello A, Daburon S, Castroviejo M, Moreau JF, Dechanet-Merville J, Taupin JL. PLoS One. 2013 Aug 26;8(8):e73375. PMID: 23991192 2- Functional characterization of a chimeric soluble Fas ligand polymer with in vivo anti-tumor activity. Daburon S, Devaud C, Costet P, Morello A, Garrigue-Antar L, Maillasson M, Hargous N, Lapaillerie D, Bonneu M, Dechanet-Merville J, Legembre P, Capone M, Moreau JF, Taupin JL. PLoS One. 2013;8(1):e54000. PMID: 23326557